TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Kairos Pharma, Ltd. ( (KAPA) ) has issued an announcement.
On September 3, 2025, Kairos Pharma announced its participation in the World Lung Cancer Conference, where Dr. Karen Reckamp will present initial Phase 1 data on the combination therapy of ENV105 with osimertinib for non-small cell lung cancer. The open-label trial primarily aims to evaluate the safety and tolerability of this combination therapy, potentially impacting the company’s operations by advancing its position in oncology therapeutics and addressing unmet medical needs in cancer treatment.
The most recent analyst rating on (KAPA) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Kairos Pharma, Ltd. stock, see the KAPA Stock Forecast page.
More about Kairos Pharma, Ltd.
Kairos Pharma, Ltd., based in Los Angeles, California, is a clinical-stage biopharmaceutical company focused on developing innovative cancer therapeutics. The company utilizes structural biology to address drug resistance and immune suppression in cancer, with its lead candidate, ENV105, targeting CD105 to reverse drug resistance and enhance the effectiveness of standard therapies across multiple cancer types.
Average Trading Volume: 5,301,559
Technical Sentiment Signal: Strong Buy
See more insights into KAPA stock on TipRanks’ Stock Analysis page.